Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.

[1]  N. Maitland,et al.  Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis , 2004, British Journal of Cancer.

[2]  D. Hallahan,et al.  XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer , 2004, Oncogene.

[3]  M. Scaltriti,et al.  Intracellular Clusterin Induces G2-M Phase Arrest and Cell Death in PC-3 Prostate Cancer Cells1 , 2004, Cancer Research.

[4]  M. Scaltriti,et al.  Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. , 2004, The Biochemical journal.

[5]  L. Milas,et al.  CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation , 2004, Cancer Research.

[6]  M. Gleave,et al.  Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. , 2004, Molecular cancer therapeutics.

[7]  M. Gleave,et al.  Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress , 2004, Cancer Research.

[8]  V. Budach,et al.  Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21WAF1/CIP1 , 2003, Cancer Gene Therapy.

[9]  M. Gleave,et al.  Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model , 2003, BJU international.

[10]  J. O’Sullivan,et al.  Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis , 2003, Cell Death and Differentiation.

[11]  D. Michel,et al.  Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration , 2003, Journal of Cell Science.

[12]  V. Dragowska,et al.  Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  D. Boothman,et al.  Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein* , 2003, The Journal of Biological Chemistry.

[14]  D. Boothman,et al.  Repression of IR-Inducible Clusterin Expression by the p53 Tumor Suppressor Protein , 2003, Cancer biology & therapy.

[15]  Q. Hasan,et al.  Effects of five commonly used glucocorticoids on haemangioma in vitro ¶ , 2003, Clinical and experimental pharmacology & physiology.

[16]  M. Gleave,et al.  Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  D. Hallahan,et al.  Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. , 2002, Cancer research.

[18]  J. Carver,et al.  Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off‐folding pathway , 2002, FEBS letters.

[19]  Takashi Ishikawa,et al.  VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice , 2002, Cancer Gene Therapy.

[20]  H. Miyake,et al.  Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Gleave,et al.  Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. , 2001, Urology.

[22]  M. Gleave,et al.  Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti‐apoptotic genes upregulated after androgen withdrawal to delay androgen‐independent progression and enhance chemosensitivity , 2001, International journal of urology : official journal of the Japanese Urological Association.

[23]  D. Fabbro,et al.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. , 2000, Cancer research.

[24]  D. Boothman,et al.  Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Miyake,et al.  Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  H. Miyake,et al.  Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. , 2000, Cancer research.

[27]  M. Gleave,et al.  Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. , 2000, Journal of the National Cancer Institute.

[28]  M. Gleave,et al.  Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. , 1999, Cancer research.

[29]  A. Bagg,et al.  Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. , 1999, Antisense & nucleic acid drug development.

[30]  J. Carver,et al.  Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins* , 1999, The Journal of Biological Chemistry.

[31]  J. O’Sullivan,et al.  Clusterin Biogenesis Is Altered during Apoptosis in the Regressing Rat Ventral Prostate* , 1998, The Journal of Biological Chemistry.

[32]  D. Fabbro,et al.  Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.

[33]  N. Kyprianou,et al.  bcl‐2 over‐expression delays radiation‐induced apoptosis without affecting the clonogenic survival of human prostate cancer cells , 1997, International journal of cancer.

[34]  B. Calabretta,et al.  In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. , 1996, Cancer research.

[35]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[36]  P. Howe,et al.  Transforming Growth Factor β (TGFβ)-Induced Nuclear Localization of Apolipoprotein J/Clusterin in Epithelial Cells† , 1996 .

[37]  R. Wagner.  The state of the art in antisense research , 1995, Nature Genetics.

[38]  M E Rosenberg,et al.  Clusterin: physiologic and pathophysiologic considerations. , 1995, The international journal of biochemistry & cell biology.

[39]  M. Griswold,et al.  Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). , 1995, Cancer research.

[40]  L. French,et al.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. , 1992, The Journal of clinical investigation.

[41]  C. Olsson,et al.  SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. , 1991, Kidney international.

[42]  M. Gleave,et al.  Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. , 2002, Urology.

[43]  M. Gleave,et al.  Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. , 2001, Neoplasia.

[44]  H. Miyake,et al.  Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.

[45]  S. Yeh,et al.  Isolation of Ku70-binding proteins (KUBs). , 1999, Nucleic acids research.

[46]  A. Hanlon,et al.  Hypoxic regions exist in human prostate carcinoma. , 1999, Urology.

[47]  C. Morgans,et al.  Clusterin: a role in cell survival in the face of apoptosis? , 1996, Progress in molecular and subcellular biology.

[48]  S. Crooke.  Therapeutic Applications of Oligonucleotides , 1992, Bio/Technology.

[49]  N. Davidson,et al.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.